A Study of the Safety, Tolerability and Pharmacokinetics of HMPL-523
Completed
Hutchison Medipharma Limited
Phase 1
The primary objective of this study is to assess the safety and tolerability of a single dose
of up to 800 mg in Part A (evaluated in planned steps of 5, 20, 50, 100, 200, 300 mg under
fasted conditions, followed by 300, 400, 600 and 800 mg HMPL-523 under fed conditions of a
standard meal, followed by multiple doses of 200, 300, 400 and 500 mg of HMPL-523 in Part B,
in healthy male volunteers.
The secondary objective is to determine the pharmacokinetic profile of single (Part A) and
multiple (Part B) oral doses of HMPL-523 in healthy male volunteers and to determine the
preliminary effect of food (Part C）
A Study of HMPL-523 in Relapsed or Refractory Hematologic Malignancies
Active, not recruiting
Iqvia Pty Ltd
Phase 1
The purpose of this study is to evaluate the safety and tolerability of HMPL-523 administered
to patients with relapsed or refractory Hematologic Malignancies
To determine the maximum tolerated dosage/recommended phase 2 dosage and characterize the
dose limited toxicities associated with HMPL-523 when administered to patients with relapsed
or refractory Hematologic Malignancies
A Study of HMPL-523 in Relapsed or Refractory Hematologic Malignancies
Active, not recruiting
Hutchison Medipharma Limited
Phase 1
The purpose of this study is to evaluate the safety and tolerability of HMPL-523 administered
to patients with relapsed or refractory Hematologic Malignancies
To determine the maximum tolerated dosage/recommended phase 2 dosage and characterize the
dose limited toxicities associated with HMPL-523 when administered to patients with relapsed
or refractory Hematologic Malignancies
A Study of Hutchison MediPharma Limited(HMPL)-523 in Patients With Relapsed or Refractory Mature B-cell Neoplasms
Unknown status
Hutchison Medipharma Limited
Phase 1
A Phase I, Open-label, Dose-escalation Study of the Safety and Pharmacokinetics of HMPL-523
in Patients With Relapsed or Refractory Mature B-cell Neoplasms
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
